Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10x Genomics, Inc. reports developments in single cell and spatial biology, including financial results, product launches and collaborations tied to its research platforms. The company sells integrated instruments, consumables and software used by academic, translational and biopharmaceutical researchers to analyze biological systems at single-cell and spatial resolution.
Recurring updates cover platforms such as Chromium, Visium, Xenium and Atera; consumables demand; spatial whole-transcriptome analysis; research collaborations and data-generation initiatives; conference presentations; and management commentary on revenue, cash resources and outlook. Company news also reflects applications in oncology, immunology, neuroscience and other disease research areas.
Bioptimus (TXG) launched STELA, a multinational spatial biology atlas anchored by partnerships with 10x Genomics and Broad Clinical Labs. STELA aims to profile up to 100,000 patient specimens (~20x current scale) across oncology and immunology, integrating Xenium spatial transcriptomics, multi-omics, histopathology imaging, and longitudinal clinical data across the US, Europe, and Asia.
STELA will feed Bioptimus' M-Optimus foundation model, standardizing data generation, harmonized processing, and AI-driven quality control to enable large-scale, reproducible datasets for translational research and therapeutic discovery.
PerturbAI emerged from stealth on March 17, 2026, releasing the world's largest in vivo CRISPR atlas: an 8 million–cell, brain-wide dataset generated with NVIDIA, Allen Institute for Brain Science, and 10x Genomics (Nasdaq: TXG).
The atlas maps thousands of genetic perturbations across hundreds of neuronal cell types, enabling organism-level, circuit-resolved causal genomics and AI-driven therapeutic discovery. PerturbAI closed an oversubscribed pre-seed round in Q3 2025.
10x Genomics (Nasdaq: TXG) said management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:50 a.m. ET. A live webcast will be available via the company's Investors website and archived for at least 30 days.
10x Genomics (Nasdaq: TXG) reported Q4 2025 revenue of $166.0M (+1% YoY) and full-year 2025 revenue of $642.8M. Excluding $44.1M of non-recurring litigation revenue, 2025 revenue was $598.7M (‑2% YoY). Cash and marketable securities totaled $523.4M. Gross margin was 69% for FY2025; operating loss narrowed to $61.0M and net loss to $43.5M. 2026 revenue guidance is $600M–$625M (0%–4% growth ex-litigation).
10x Genomics (Nasdaq: TXG) announced a partnership with PharosAI, a UK consortium of four institutions, to build one of the world's largest multimodal cancer datasets using the Xenium spatial platform.
Backed by £18.9 million from the UK Research Ventures Catalyst and partners, the program will convert thousands of archived NHS cancer samples into AI-ready genomic, transcriptomic, imaging and spatial biology data, run through 2027, and democratize secure access for researchers worldwide.
10x Genomics (Nasdaq: TXG) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 12, 2026. A public conference call and live webcast for analysts and investors begins at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments and outlook. The earnings news release will be posted on the company's website prior to the call. Interested parties can access a live webcast of the fireside chat on the Investors section at https://investors.10xgenomics.com/. The webcast will be archived for replay for at least 45 days after the event.
Amcor (NYSE: AMCR) completed a 1-for-5 reverse stock split, effective with trading on a split-adjusted basis on January 16, 2026.
The split was approved by shareholders on November 6, 2025, and the memorandum of association amendment was filed on January 14, 2026. Amcor ordinary shares continue trading under AMCR on the NYSE with a new CUSIP G0250X149. CHESS Depositary Interests continue trading under AMC on a split-adjusted basis. Computershare is acting as exchange agent; registered U.S. shareholders and CDI holders have specified contact numbers for exchange questions. More details are available in Amcor's September 23, 2025 proxy and on its investor website.
10x Genomics (NASDAQ: TXG) announced a collaboration with Brigham & Women's Hospital on a blood‑based, single‑cell study of autoimmune diseases launched Jan 12, 2026. The study plans to enroll 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus and giant cell arteritis plus healthy controls, collecting peripheral blood at routine visits and pairing single‑cell Chromium Flex assays with longitudinal clinical data. The collaboration aims to identify immune signatures tied to disease activity, flare, remission and treatment response and to build a framework for a future clinical report. The program aligns with 10x's multi‑year effort, including a planned CLIA‑certified lab and other institutional partnerships.
10x Genomics (NASDAQ: TXG) announced a multi-year collaboration with Dana-Farber Cancer Institute to analyze tumor samples from hundreds of patients across major solid tumor types using single cell and spatial profiling. The initiative aims to identify biomarkers tied to treatment response, resistance and progression and to define a clinical reporting framework to support precision oncology. 10x also plans to establish a CLIA-certified laboratory to enable assay implementation, analytical validation and future diagnostic services using its Chromium Flex single cell assay and Xenium spatial platform.
10x Genomics (NASDAQ: TXG) and the Cancer Research Institute launched a multi-phase, AI-driven immuno-oncology initiative to generate high-resolution single cell and spatial data from more than 20,000 samples to map immune responses to cancer.
The project begins with a pilot to produce ~3,000 samples using 10x Chromium and Xenium to benchmark early AI models, then expands to profile over 500 million cells using Chromium Flex across a broader lab network to inform immunotherapy and vaccine discovery.